S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Investors Face November Deadline in Anavex Life Sciences Class Action

Investors who purchased Anavex Life Sciences Corp. securities between November 26, 2025, and August 28, 2026, face a November 30, 2026, deadline to seek lead plaintiff status. The pending class action lawsuit alleges the company maintained false claims regarding its internal financial controls while a former executive concealed critical regulatory data.

Investors Face November Deadline in Anavex Life Sciences Class Action
Photo: Bio & News

The litigation, filed in the United States District Court for the Southern District of New York, centers on a period where Anavex repeatedly certified its disclosure controls as effective. According to the complaint, these certifications—issued in November 2025 and February 2026—masked a material weakness that only came to light following the termination of the company's CEO for cause on April 30, 2026.

Plaintiffs contend that the company’s subsequent August 2026 filings admitted the former CEO failed to enforce compliance, effectively correcting misstatements that had persisted for nearly nine months. This period of uncertainty triggered multiple stock price declines, including drops in May and August 2026. Managing partner Joseph E. Levi of Levi & Korsinsky, LLP, which is representing the class, noted that shareholders who acquired securities during this window may be eligible to recover damages regardless of whether they currently hold the shares.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!